The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Pfizer Inc

NYSE: PFE
Last

(U.S.) $30.69

Today's change+0.22 +0.71%
Updated November 26 12:28 PM EST. Delayed by at least 15 minutes.
 

Pfizer Inc

NYSE: PFE
Last

(U.S.) $30.69

Today's change+0.22 +0.71%
Updated November 26 12:28 PM EST. Delayed by at least 15 minutes.

Pfizer Inc Hits New 20-day High

Pfizer Inc is up today by (U.S.)$0.22 or 0.71% to (U.S.)$30.69 and setting a new 20-day high. Over the last five days, shares have gained 0.80%, but are currently unchanged over the last year to date. Shares have underperformed the S&P 500 by 18.57% during the last year.

Key company metrics

  • Open(U.S.) $30.65
  • Previous close(U.S.) $30.47
  • High(U.S.) $30.82
  • Low(U.S.) $30.59
  • Bid / Ask(U.S.) $30.68 / (U.S.) $30.69
  • YTD % change+0.18%
  • Volume9,175,939
  • Average volume (10-day)21,907,932
  • Average volume (1-month)22,177,857
  • Average volume (3-month)24,563,794
  • 52-week range(U.S.) $27.51 to (U.S.) $32.96
  • Beta0.69
  • Trailing P/E19.41×
  • P/E 1 year forward13.56×
  • Forward PEG10.84×
  • Indicated annual dividend(U.S.) $1.04
  • Dividend yield3.39%
  • Trailing EPS(U.S.) $1.58
Updated November 26 12:28 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+20.97%

Based on its net profit margin of 20.97%, Pfizer Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.19%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 28, 201409/28/2014Jun 29, 201406/29/2014Mar 30, 201403/30/2014Dec 31, 201312/31/2013
Revenue12,36112,77311,35351,584
Total other revenue--------
Total revenue12,36112,77311,35351,584
Gross profit9,99310,3279,31442,229
Total cost of revenue2,3682,4462,0399,355
Total operating expense8,6218,5998,44035,428
Selling / general / administrative3,5433,5203,04014,191
Research & development1,8021,7591,6236,551
Depreciation / amortization9721,0011,1174,599
Interest expense (income), net operating--------
Unusual expense (income)265958731,057
Other operating expenses, total-329-222-252-325
Operating income3,7404,1742,91316,156
Interest income (expense), net non-operating-343-343-321-1,414
Gain (loss) on sale of assets5333181320
Other--------
Income before tax3,5874,0032,84715,716
Income after tax2,6762,9212,26511,410
Income tax, total9111,0825824,306
Net income2,6672,9122,32922,003
Total adjustments to net income-1-10-2
Net income before extra. items2,6702,9122,25611,380
Minority interest-6-9-9-30
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items2,6692,9112,25611,378
Inc. avail. to common incl. extra. items2,6662,9112,32922,001
Diluted net income2,6662,9122,32922,003
Dilution adjustment--1--2
Diluted weighted average shares6,4036,4446,4766,895
Diluted EPS excluding extraordinary itemsvalue per share0.420.450.351.65
Dividends per sharevalue per share0.260.260.260.96
Diluted normalized EPSvalue per share0.450.450.451.73